Compare VET & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VET | ANAB |
|---|---|---|
| Founded | 1994 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2004 | 2015 |
| Metric | VET | ANAB |
|---|---|---|
| Price | $10.91 | $47.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $15.39 | ★ $87.25 |
| AVG Volume (30 Days) | ★ 1.6M | 382.4K |
| Earning Date | 11-04-2026 | 11-24-2026 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $41.51 | N/A |
| Revenue Next Year | N/A | $69.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $7.76 | $32.96 |
| 52 Week High | $14.82 | $73.30 |
| Indicator | VET | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 37.27 | 48.62 |
| Support Level | $9.93 | $44.25 |
| Resistance Level | $10.92 | $51.54 |
| Average True Range (ATR) | 0.51 | 1.72 |
| MACD | -0.28 | 0.24 |
| Stochastic Oscillator | 24.82 | 49.28 |
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe while optimizing low-decline oil assets. Its operating segments are: Canada, France, Netherlands, Germany, Ireland, Australia, and CEE, each representing the oil and gas exploration operations at its assets located in these regions. The company mainly derives revenue from the production and sale of petroleum and natural gas. The majority of its revenue is generated from Canada, where the company's operations are mainly focused on the Deep Basin trend in the West Pembina region of Alberta and on the Mica property.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).